The research collaboration will start with the examination of the seven transporters cited by the International Transporter Consortium and the FDA as the most clinically relevant to transporter-related drug-drug interactions using Optivia’s novel polarised mammalian cell assays transporter technology platform.
Optivia and the FDA will then analyse and interpret the drug transporter data as preparation for publishing the results.
Optivia Biotechnology president and CEO Yong Huang said that the project advances Optivia’s position in the development of quantitative tools for optimising the safety and efficacy of drugs.